REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022, at 11:00 a.m. ET. The panel will focus on Unique Delivery Technology Platforms for Better Compliance and Efficacy. A live webcast will be accessible on the company's website, followed by an archived replay for 30 days. REGENXBIO is a clinical-stage biotechnology company harnessing gene therapy through its proprietary NAV Technology Platform, which includes over 100 exclusive AAV vectors, supporting its goal of advancing five AAV Therapeutics by 2025.

Positive

• The company’s NAV Technology Platform offers exclusive rights to over 100 novel AAV vectors, enhancing its research capabilities.
• Commitment to a '5x'25' strategy aims to progress five AAV Therapeutics to pivotal or commercial stages by 2025.

Negative

• None.

ROCKVILLE, Md., Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17th, 2022:

Panel: Unique Delivery Technology Platforms for Better Compliance and Efficacy
Date: Wednesday, August 17^th, 2022
Time: 11:00 a.m. ET

A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-hc-wainwright-2nd-annual-ophthalmology-virtual-conference-301603169.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO's presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference?

REGENXBIO's presentation will be on August 17, 2022, at 11:00 a.m. ET.

What is the focus of REGENXBIO's presentation at the conference?

The presentation will focus on Unique Delivery Technology Platforms for Better Compliance and Efficacy.

How can I access the REGENXBIO conference presentation?

The live webcast will be available in the Investors section of REGENXBIO's website.

What is the goal of REGENXBIO's '5x'25' strategy?

The goal is to advance five AAV Therapeutics into pivotal or commercial stages by 2025.

What is the NAV Technology Platform used by REGENXBIO?

The NAV Technology Platform is a proprietary adeno-associated virus gene delivery platform with exclusive rights to over 100 novel AAV vectors.